Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.07 -0.08 (-3.72%) Market Cap: 416.86 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.14 GF Score: 31/100

Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 09:30PM GMT
Release Date Price: $24.6 (+2.46%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. I'm Salveen Richter Biotechnology analyst at Goldman Sachs, and we're pleased to have with us Taysha. And with us from the company, we have R.A. Session, CEO; Suyash Prasad, Chief Medical Officer and Head of R&D; and Kim Lee, Head of IR. And with that, all right, thanks for joining us.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And maybe to level set and start here. Could you remind us of the catalyst path for you. And in 2021, you're clearly focused on neurology diseases within -- with gene therapy and have taken quite a few drugs into the pipeline, and we're looking for first proof-of-concepts. So would love to hear.

R. A. Session
Taysha Gene Therapies, Inc. - Founder, President, CEO & Director

Yes, absolutely. And Salveen, thank you guys for having us over at Goldman. I would probably say you guys have the best intro music of the pandemic, just so you know

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot